Epigenetics and Cancer Therapy

T-NHL subtypes and clinical perspective

H Miles Prince

2021-07-01

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients With Steroid-refractory Acute GRAFT-VS-HOST Disease (SR-AGVHD): 6-Month Follow-up From The Randomized, Phase 3 Reach2 Study

Mohamad Mohty, Claude-Eric Bulabois, Valentin Garcia-Gutierrez, David Ritchie, Sung-Soo Yoon, Valerie Coiteux, Yok-Lam Kwong, Dietger Niederwieser, Reuven Or, Gerard Socie, Nikolas von Bubnoff, Robert Zeiser, Judith Xu, Juliane Morando, Bruyere Mahuzier, Jeff Szer

2021-06-01